Modified Release
The demand for modified-release formulations is driven by many factors related to both patient and therapeutic needs. For most conditions, patients generally demand either once-daily or twice-daily treatments, requiring sustained drug concentrations throughout the treatment period.
Modified-release formulations are designed to deliver your drug over a defined period of time and/or to a particular region of the body. By doing this, drug delivery can be optimized to balance therapeutic need, manage adverse event (AE) profiles, and reduce dosing frequency, which contribute to improved patient compliance.
Quotient Sciences has extensive experience in designing modified-release formulations, from gastro-retention to sustained-release and pulsatile-release formats. Learn more about how we can help tailor your programs in our latest info sheet.
| Modified-release format | Objective | Formulation technology |
| Gastro-retention |
|
Swellable tablets (monolithic, bilayer, trilayer) |
| Gastro-resistant |
|
Enteric-coated tablets or capsules |
| Sustained or extended release |
|
Matrix tablets, coated tablets, or multiparticulates |
| Targeted or controlled delivery |
|
Tablets, capsules, or multiparticulates |
| Biphasic release |
|
Bilayer tablets or multiparticulates |
| Pulsatile release |
|
Bilayer tablets or multiparticulates |
Improve your clinical and commercial outcomes
Expert support for your modified-release programs
Although modified-release formulations can offer many therapeutic benefits for both drug developers and patients, there are several challenges to overcome when trying to develop this type of formulation. With over 30 years of expertise, Quotient Sciences can help with even the most challenging modified-release programs.
Access our latest info sheet to find out how our modified-release formulation strategies and technologies can help your molecule achieve clinical and commercial success.
Learn more about modified-release formulation development
-
WhitepaperStrategies for Accelerating the Development of Modified Release Oral FormsMR drug delivery can also have commercial benefits and is prevalent as part of product life-cycle management (LCM). Modest reformulation of an already approved drug from an IR to MR format allows both line and patent extension opportunities and continued market exclusivity.
-
WhitepaperAlternative Strategies for Development of Modified Release Dosage FormsModified-release (MR) formulations are in high demand. For formulators, they enable drugs to be released in the optimal gastrointestinal (GI) locations to achieve and maintain desirable plasma concentrations for extended periods, avoiding undesirable excursions outside the therapeutic range.
-
Info SheetTranslational Pharmaceutics® Fact SheetQuotient Sciences helps you achieve your goals by enabling precise formulation development, streamlined manufacturing, quick pivot to clinical data and a significantly faster transition through drug development.
-
Info SheetGlobal Formulation Development and Manufacturing CapabilitiesWe provide full service support for small molecule non-sterile programs, from dosage formulation development through to GMP clinical trial manufacturing and commercial drug product supply.